Our Webinar Series will continue on June 24th! Join thousands of your peers in WCG’s online panels, where clinical trial and public health experts provide the latest insights on COVID-19 and discuss the biggest questions and topics you submit.
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
From January to May 2020, monthly non-COVID-19 trial starts averaged only 71% of last year’s pace, with the biggest drop unsurprisingly occurring in April and May. During those two months, starts dropped to half of last year’s starts in the same time frame.
However, if June continues at the current pace, it will likely meet or exceed June 2019 starts. That represents not only the highest percentage gain since the COVID-19 crisis, but also the nearest to 2019 levels so far this year.
Approximately 35% of non-COVID-19 industry sponsored trials planned and started in the US after May 1 are in oncology. The hastened recovery in certain therapeutic areas comes as sites and sponsors seek to address patients in need of critical care.
This week, 75% of sites indicated readiness to restart screening within the next four weeks – an appreciable jump since we began tracking in April. Meanwhile, only 4% are still uncertain about their timing for restarting – the lowest percentage since our surveys began, and a drop of 18 percentage points since June 9.
WCG is tracking more than 1,400 sites in 29 countries to understand how quickly total trial enrollment is being affected during the pandemic. 37% of sites responding are now open to enrollment of new participants, up 7 percentage points from last week, and our largest percentage increase since tracking began in March.
News provided by WCG FDAnews and WCG CenterWatch
Pfizer and BioNTech Report Positive Results From COVID-19 Vaccine Trial
Pfizer and BioNTech have announced positive early results from a phase 1/2 study of their lead COVID-19 vaccine candidate in the U.S.
Fujifilm Partners With Dr. Reddy’s to Sell Avigan for COVID-19
Japanese drugmaker Fujifilm is partnering with India’s Dr. Reddy’s and Dubai-based Global Response Aid (GRA) to manufacture and sell its influenza drug Avigan (favipiravir) for the treatment of COVID-19.
Some Government Contracts for COVID-19 Products Dodge Affordable Pricing Laws, Report Says
At least five drug developers working on COVID-19 therapeutics and vaccines with U.S. government funding have contracts that bypass laws that ensure taxpayer-funded drugs and vaccines are affordable, a new report says.
Drugmakers Raised Drug Prices Throughout COVID-19 Pandemic, Analysis Finds
Drugmakers have continued to hike their drug prices during the COVID-19 crisis, increasing prices on average 23.8 percent for 245 drugs, many of which are used in COVID-19 treatments or research.
Kroger’s COVID-19 Test Home Collection Kit Cleared for Emergency Use
The agency said promotional material for the home collection kit must make clear that it has not been FDA cleared or approved.
FDA Outlines Required COVID-19 Vaccine Data in New Guidance
Any COVID-19 vaccine the FDA approves would have to be at least 50 percent more effective than a placebo, according to a new guidance it released yesterday.
Hahn Predicts Multiple COVID-19 Treatments by Fall
FDA Commissioner Stephen Hahn said yesterday that he was “optimistic” that more than one COVID-19 treatment could be available by the fall in addition to Gilead Sciences’ remdesivir, which has already received Emergency Use Authorization from the agency.
Oxford to Resume Global Trial of Hydroxychloroquine to Prevent COVID-19
The University of Oxford is resuming recruitment this week for its global clinical trial of hydroxychloroquine and chloroquine, which was paused after a now-retracted study found the antimalarial drugs had no benefit as a treatment for COVID-19.
Inovio’s Vaccine Candidate Shows Promise in Early Trial
Inovio Pharmaceuticals has released data from the phase 1 clinical trial of its COVID-19 vaccine candidate showing it was safe and well-tolerated and induced immune responses in a majority of participants.
Bharat Biotech Gets Indian Approval for COVID-19 Vaccine Trials
Bharat Biotech has received approval to begin clinical trials in India of its COVID-19 vaccine candidate. The trial will be the first for a COVID vaccine developed in that country.
Gilead Sciences Prices Remdesivir at $3,120 Per Treatment
After weeks of waiting, Gilead Sciences announced yesterday that it will charge U.S. insurers $3,120 for a six-vial, five-day course of remdesivir, and a lower price of $2,340 for governments of developed countries, including the U.S.
Oxford University Begins Phase 3 COVID-19 Vaccine Trial in Brazil
The University of Oxford is ready to launch a phase 3 trial in Brazil of AstraZeneca (AZ)’s COVID-19 vaccine candidate, considered by the World Health Organization (WHO) to be the frontrunner in the research race.
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.